Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

328 total articles

Why Sportradar (SRAD) Is One of My Highest-Conviction Longs for 2026

Why Sportradar (SRAD) Is One of My Highest-Conviction Longs for 2026

Sportradar is a market leader in sports data and betting technology with accelerating margins, a string of strategic deals (IMG ARENA, Bundesliga expansion), active buybacks and a current technical oversold setup. At a market cap of ~$5.8B and rich but justifiable growth expectations, I view SRAD as a long-term trade for investors willing to tolera…

Buy HTGC for Yield and Upside: A Retirement-Friendly BDC Trade

Buy HTGC for Yield and Upside: A Retirement-Friendly BDC Trade

Hercules Capital (HTGC) offers an 8%-9% yield, a modest P/E near 11 and a P/B around 1.5. For income-seeking investors who can tolerate credit and rate volatility, HTGC presents a balanced long trade: collect a high dividend while holding for potential capital appreciation as credit performance and rate expectations normalize.

Chemours 2026: Re-rate Catalyzed by HFE Shortage and Opteon Momentum

Chemours 2026: Re-rate Catalyzed by HFE Shortage and Opteon Momentum

Chemours (CC) looks set to re-rate in 2026 as tight supply for high-purity hydrofluoroethers, steady demand for Opteon refrigerants, and improving technical momentum combine with a cheap starting valuation versus enterprise value. We present a long trade with entry at $15.10, stop at $13.00 and a $22.00 target over a 46-180 trading day time frame.

Buy EXEL Ahead of a Potential FDA Win — Risk-Weighted Mid-Term Trade

Buy EXEL Ahead of a Potential FDA Win — Risk-Weighted Mid-Term Trade

Exelixis (EXEL) is a profitable oncology company trading near $42.67 with solid free cash flow, low leverage and a pipeline catalyst in zanzalintinib. A favorable FDA outcome could push the stock toward the mid-$40s to $50s; the trade below balances upside with a clear stop and a mid-term time horizon tied to a likely near-term regulatory event.

QuantumScape: From Options Trade to Manufacturing Blueprint

QuantumScape: From Options Trade to Manufacturing Blueprint

QuantumScape has moved beyond lab headlines into real vehicle testing and pilot production. With a market cap near $6.0B and a string of OEM and materials partnerships, the risk/reward favors a disciplined long position that targets bet-the-technology upside while protecting capital against execution failure.

Okta: How AI Agents Can Turn Identity Into a New Revenue Engine

Okta: How AI Agents Can Turn Identity Into a New Revenue Engine

Okta sits squarely at the intersection of identity and emergent enterprise AI agents. Identity is a prerequisite for secure agent actions; that makes Okta a natural beneficiary if customers adopt agentic workflows widely. Valuation already reflects a pullback from the 52-week high and a $1 billion buyback set to cushion share count. This trade targ…

Alico: Hidden Land Value and a Path to Re-Rating

Alico: Hidden Land Value and a Path to Re-Rating

Alico (ALCO) is a small-cap agricultural holding that is quietly pivoting from pure citrus production toward land management and real estate monetization. With a newly expanded $95M credit facility, a dedicated EVP of Real Estate, and management guidance for ~$20M in land sales this fiscal year, the stock looks positioned for a re-rating if managem…

Buy Mercado Libre: Own Latin America's E-commerce + Fintech Compounder

Buy Mercado Libre: Own Latin America's E-commerce + Fintech Compounder

Mercado Libre (MELI) is the dominant e-commerce and fintech platform across Latin America. With rising transaction take-rates, accelerating fintech adoption, and $8.61B in free cash flow, MELI offers a compounding growth story. This trade idea lays out an actionable long trade with entry at $2270.23, a $2850 target and a $2000 stop loss over a long…

Dycom: Tactical Long Into Data-Center Momentum With Defined Risk

Dycom: Tactical Long Into Data-Center Momentum With Defined Risk

Dycom's pivot into data-center electrical work and a record backlog make a compelling tactical long. The balance sheet, free cash flow and recent operational beats underwrite a trade that targets continued contract wins and integration upside from Power Solutions. This is a risk-managed idea — entry at $372, stop $350, target $420 — with clear trig…

Buy CSIQ on AI-Driven Storage Demand; Expect a Gradual Rerating

Buy CSIQ on AI-Driven Storage Demand; Expect a Gradual Rerating

Canadian Solar (CSIQ) is positioned to monetize accelerating AI-related power needs through battery energy storage systems (BESS) and long-term project agreements. The market is only beginning to price that optionality; however, high cyclicality, execution risk in project development, and heavy short interest mean multiple expansion is likely to co…

Toyota Looks Cheap and Ready to Run: A Swing Trade With Upside to $245

Toyota Looks Cheap and Ready to Run: A Swing Trade With Upside to $245

Toyota (TM) is trading at a modest multiple, pays a 2.5% yield, and sits on clear near-term catalysts — from auto-show exposure to strengthening demand for fuel-cell and ICE hybrids. Technicals are mixed, but fundamentals and valuation give a favorable asymmetric trade. This idea outlines an entry at $219.00, a stop at $205.00 and a first target of…

Vistra Pullback: Accounting Optics, Not a Fundamental Reversal

Vistra Pullback: Accounting Optics, Not a Fundamental Reversal

Vistra (VST) appears to be experiencing a headline-driven retreat rather than a fundamental slowdown. Power contracts and cash flow remain intact, but accounting line items tied to asset closure and decommissioning can compress reported earnings and spook short-term holders. This trade targets a mean reversion back above the 50-day SMA with a clear…